Sugi Predict

Sugi Predict / Compounds / SCHEMBL4022191

SCHEMBL4022191

SCHEMBL4022191

COC(=O)C(C)(c1ccccc1)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNN4 O15554 1/20 0.67
▸ HDAC3 O15379 1/20 0.59
▸ HDAC4 P56524 1/20 0.59
▸ HDAC1 Q13547 1/20 0.59
▸ HDAC7 Q8WUI4 1/20 0.59
▸ HDAC2 Q92769 1/20 0.59
▸ HDAC10 Q969S8 1/20 0.59
▸ HDAC11 Q96DB2 1/20 0.59
▸ HDAC8 Q9BY41 1/20 0.59
▸ HDAC6 Q9UBN7 1/20 0.59
▸ HDAC9 Q9UKV0 1/20 0.59
▸ HDAC5 Q9UQL6 1/20 0.59
▸ CHRM2 P08172 4/20 0.51
▸ CHRM4 P08173 4/20 0.51
▸ CHRM1 P11229 4/20 0.51
▸ CHRM3 P20309 4/20 0.51
▸ CHRM5 P08912 3/20 0.51
▸ SRC P12931 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.49
▸ MAPT P10636 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9778358 0.91 CHRM2 (0.57) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL9778284 0.89 KCNN4 (0.55) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL28677835 0.86 KCNN4 (0.51) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL27622326 0.85 KCNN4 (0.50) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL17681401 0.84 HDAC3 (0.55) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL9778344 0.83 POLB (0.58) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL728471 0.83 KCNN4 (0.67) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL16732028 0.83 KCNN4 (0.67) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL5796685 0.82 KCNN4 (0.51) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL834511 0.81 CHRM2 (0.53) KCNN4CHRM2CHRM4CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030036489-A1 Consumable composition comprising perfumed particles and article containing the same THE PROCTER & GAMBLE COMPANY 2003-02-20 — — US claimed
WO-2002090479-A1 PERFUMED PARTICLES AND ARTICLES CONTAINING THE SAME THE PROCTER & GAMBLE COMPANY (US) 2002-11-14 — — WO claimed
WO-2002090481-A1 COMPOSITIONS AND ARTICLES FOR EFFECTIVE DEPOSITION OF PERFUME THE PROCTER & GAMBLE COMPANY (US) 2002-11-14 — — WO claimed
CN-116507606-A TES-based cationic lipids 翻译生物公司 2023-07-28 — — CN disclosed
CN-116457027-A Piperazine-based cationic lipids 翻译生物公司 2023-07-18 — — CN disclosed
CN-104592129-A Improved method used for preparing ambrisentan QR PHARMACEUTICALS LTD 2015-05-06 — — CN disclosed
CN-101768108-A Pyridine ring-substituted alpha-hydroxycarboxylic acid derivatives, preparation method thereof and use thereof TIANJIN INST PHARM RESEARCH 2010-07-07 — — CN disclosed
WO-2009139710-A1 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2009-11-19 — — WO disclosed
WO-2009139710-A1 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2009-11-19 — — WO disclosed
CN-101573340-A Modulators of glucocorticoid receptor AP-1 and/or NF-kB activity and uses thereof BRISTOL MYERS SQUIBB CO (US) 2009-11-04 — — CN disclosed
US-7569581-B2 Anticholinergics which may be used as medicaments as well as processes for preparing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-08-04 — — US disclosed
US-20020115680-A1 Anticholinergics which may be used as medicaments as well as processes for preparing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-08-22 — — US disclosed
WO-2002032899-A1 NOVEL ANTICHOLINERGIC AGENTS THAT CAN BE USED AS MEDICAMENTS AND METHOD FOR THE PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-04-25 — — WO disclosed
CN-1081625-C 1 -aryl -2 -acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists NOVARTIS AG (CH) 2002-03-27 — — CN disclosed
CN-1251991-A Carboxylic acid derivatives, their preparation and their use in cancer therapy BASF AG (DE) 2000-05-03 — — CN disclosed
CN-1233238-A Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists NOVARTIS AG (CH) 1999-10-27 — — CN disclosed
US-5827868-A Prostaglandin analogs E. R. SQUIBB & SONS, INC. (US) 1998-10-27 — — US disclosed
CN-1175944-A 1 -aryl -2 -acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists CIBA GEIGY AG (CH) 1998-03-11 — — CN disclosed
US-4898941-A Process for preparing diphenylalkene derivatives KANZAKI PAPER MANUFACTURING CO., LTD. (JP) 1990-02-06 — — US disclosed
EP-0257591-A2 Process for preparing diphenylalkene derivatives KANZAKI PAPER MANUFACTURING CO., LTD. (JP) 1988-03-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115680-A1 Anticholinergics which may be used as medicaments as well as processes for preparing them CHRM2, CHRM1, CHRM5 KCNN4 1089/4885HDAC3 2467/4885HDAC4 1403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.